摘要
临床药师对2例心脏机械瓣膜置换术患者实施基因导向的华法林个体化抗凝治疗。1例基因型为CYP2C9*3(CC),VKORC1-1639AA患者的剂量降低,而另1例基因型为CYP2C9*3(AA),VKORC1-1639GA患者的剂量升高,二者均达到较好的抗凝效果。
Clinical pharmacist participated in 2 cases of individualized anticoagulant therapy with war-farin based on gene polymorphism for patients after mechanical cardiac valve replacement. For the patient with genotype of CYP2C9*3 (CC), VKORC1-1639AA, her warfarin doses were reduced, while for the geno-type of CYP2C9*3 (AA), VKORC1-1639GA, her warfarin doses were elevated. Both of the two cases ob-tained satifactory anticoagulant effect.
出处
《药学与临床研究》
2015年第4期402-403,共2页
Pharmaceutical and Clinical Research
关键词
华法林
基因多态性
临床药师
心脏机械瓣膜置换
Warfarin
Gene polymorphism
Clinical pharmacist
Mechanical cardiac valve replacement
